View of Should age disqualify from life-prolonging therapy? Successful adjuvant immunotherapy in an 88-year-old octogenarian with melanoma and high cardiovascular risk.

Return to Article Details Should age disqualify from life-prolonging therapy? Successful adjuvant immunotherapy in an 88-year-old octogenarian with melanoma and high cardiovascular risk. Download Download PDF